(Total Views: 640)
Posted On: 11/08/2020 11:30:57 AM
Post# of 154852
"...75%...next week." Seethamraju.
No doubt, an inaccurate statement, but I'd say he probably meant that the 75%, the enrollment of 293, could ("possibly"
be "hit as soon as next week". Not the review of interim data, but the enrollment of 293. Still, way off.....
The trial for severe-to-critical Covid-19 patients, which costs about $9 million, has recruited 247 of its targeted 390 patients, Pourhassan said. The FDA has agreed to review its efficacy results at the 75% recruitment point, which could be hit as soon as next week, Seethamraju said. [...]"
No doubt, an inaccurate statement, but I'd say he probably meant that the 75%, the enrollment of 293, could ("possibly"
be "hit as soon as next week". Not the review of interim data, but the enrollment of 293. Still, way off..... The trial for severe-to-critical Covid-19 patients, which costs about $9 million, has recruited 247 of its targeted 390 patients, Pourhassan said. The FDA has agreed to review its efficacy results at the 75% recruitment point, which could be hit as soon as next week, Seethamraju said. [...]"
(2)
(0)
